Neu Health is Revolutionizing Neurology Care with $3.6 Million in Funding
London, UK, 19 October 2023 – Neuhealth Digital (‘Neu Health’), an innovative neurology healthtech spinout from the University of Oxford, is on a mission to reinvent the neurology care landscape. The company has secured $3.6 million in funding from Oxford Science Enterprises (OSE), a major stride towards making cutting-edge neurology care universally accessible.
As the prevalence of Parkinson’s Disease, dementia, and other neurodegenerative conditions continues to rise, with a projected 200 million individuals worldwide affected by 2050, Neu Health empowers clinicians, caregivers, and patients to confront this mounting challenge. The company combines an analytics platform with a user-friendly smartphone app and a clinician dashboard to make the latest care accessible to everyone.
Neu Health’s approach is built on decade's worth of longitudinal data, extensive research, disease progression analysis, and rigorous clinical validation by a team of experts, including neurologists, neuroscientists, and data scientists from the University of Oxford.
The technology offers actionable insights through a clinician dashboard catering to the entire Multi-Disciplinary Team, comprising neurologists, specialist nurses, psychiatrists, geriatricians, general practitioners, physiotherapists, speech and language therapists, pharmacists, and occupational therapists. Developed in close collaboration with both patients and clinicians, Neu Health's platform enables those with Parkinson’s and dementia to become active partners in their care, helping them to adhere to care plans, preserve their independence and reduce their reliance on high-acuity care.
“This investment empowers us to bring groundbreaking technologies to these high-need populations, ultimately transforming clinical outcomes and enhancing the quality of life for people living with neurodegenerative conditions.”
Caroline Cake, CEO of Neu Health, underscores the significance of their mission, stating, "Parkinson’s Disease and Dementia are among the fastest-growing and most costly diseases on a global scale. Yet, the management of these complex conditions is in its infancy. This investment empowers us to bring groundbreaking technologies to these high-need populations, ultimately transforming clinical outcomes and enhancing the quality of life for people living with neurodegenerative conditions."
Heather Roxborough, Head of HealthTech at Oxford Science Enterprises, adds, “We’re excited to welcome Neu Health to our portfolio of companies working to address some of the world’s most pressing health challenges. With its foundation of world-class research, proven technology platform and experienced leadership, Neu Health is changing the way care is accessed and delivered to people with neurodegenerative conditions, pioneering the field of precision neurology. We look forward to working with their team to support the next phase of the company’s journey.”
About Neu Health
Neu Health is a health-tech company based in London, UK, dedicated to making the latest Parkinson’s disease and dementia care accessible to all. Established in 2022, the company leverages research, data, and clinical validation conducted by neurologists, neuroscientists, and data scientists in the laboratories of Professor Michele Hu and Professor Masud Husain at the University of Oxford.
Neu Health is proudly backed by Oxford Science Enterprises, an independent billion-pound investment company, which champions transformational businesses through its unique partnership with the University of Oxford.
About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s largest #1 research university. This partnership enables OSE to work with the brightest academic minds, tackling the world’s toughest challenges, and guarantees unrivalled access to their scientific research. In collaboration with its global network of entrepreneurs and advisers, OSE goes well beyond funding to shape and nurture these complex ideas into successful businesses.
Actively focused on a core portfolio of around 40 companies, spanning three high-growth, high-impact sectors – Life Sciences, Health Tech, and Deep Tech – the company adopts a flexible, long-term investment approach, recognising the path from ground-breaking research to global markets takes time and resilience. To date, OSE has invested £0.6 billion in over 80 ambitious companies built on Oxford Science.